27 October 2023
27 October 2023
myTrialsConnect aids patient recruitment and screens for patient eligibility through medical record reviews and chatbot-based surveys.
The DESyne BDS drug-eluting stent achieved a 1.0% target lesion failure rate compared to 8.2% by the durable polymer drug-eluting stent.
A pivotal Phase III trial will be initiated in the coming months to further evaluate the lead formulations of the combination vaccine.
The new partnership includes solutions comprising Medidata Grants Manager and Medidata AI Intelligent Trials.
Triumvira Immunologics announced that its novel TAC T-Cell therapy pipeline TAC01-HER2 has been well tolerated in a Phase I trial.
The company anticipates commencing the trial of the combination therapy mid-next year.
The trial analysed the tolerability and safety of RH324 in advanced NSCLC patients who have failed treatments previously.
There is currently no functional cure available to the estimated 296 million people living with Hepatitis B.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
